During the past decade, Toronto Digestive Disease Associates, Inc. conducted 40 clinical trials. In the 10-year time frame, 40 clinical trials started and 29 clinical trials were completed, i.e. on average, 72.5% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 25 clinical trials were completed. i.e. 833.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Toronto Digestive Disease Associates, Inc." #1 sponsor was "Celgene" with 10 trials, followed by "Shire" with 7 trials sponsored, "Hoffmann-La Roche" with 6 trials sponsored, "Takeda" with 6 trials sponsored and "Allergan" with 6 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Toronto Digestive Disease Associates, Inc." #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Algorithme Pharma Inc" with 1 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator, "Ironwood Pharmaceuticals, Inc." with 1 trials as a collaborator and "JSS Medical Research Inc." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Toronto Digestive Disease Associates, Inc." are "Ulcerative Colitis" (14 trials), "Crohn's Disease" (10 trials), "Crohn Disease" (7 trials), "Colitis, Ulcerative" (6 trials) and "Gastroparesis" (4 trials). Many other conditions were trialed in "Toronto Digestive Disease Associates, Inc." in a lesser frequency.

Most popular intervention types in "Toronto Digestive Disease Associates, Inc." are "Drug" (56 trials) and "Other" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (25 trials), "Etrolizumab" (5 trials), "Filgotinib" (4 trials), "GED-0301" (3 trials) and "Ozanimod" (3 trials). Other intervention names were less common.

The vast majority of trials in "Toronto Digestive Disease Associates, Inc." are 54 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Toronto Digestive Disease Associates, Inc.". undefined are not yet recruiting, 5 are recruiting, 8 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 33 completed trials in Toronto Digestive Disease Associates, Inc., undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Toronto Digestive Disease Associates, Inc., 2 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 41 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".